The B- part of the cases focuses on the outcome of the lawsuit against the South African government. But the demands from the NGOs keep on coming and Garnier, the CEO of GSK, is faced with some tough decisions to make. Should he allow licensing? How should he deal with parallel importation?
GlaxoSmithKline, Health Care, Pharmaceuticals
2001 - 2004
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications